View Older Stories
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE) but Does Not See ReViral Acquisition "Impactful for Pfizer's Nearer-Term P&L"
-
Pfizer boosts respiratory drug portfolio with ReViral purchase
-
BMO Capital Reiterates Pfizer (PFE) at Ourperform, $76 PT, Sees etrasimod Better Positioned vs BMY's Zeposia
-
BMO Capital Reiterates Pfizer (PFE) at Outperform, CLOVER Trial is Not Core but Substantial Attenuation in Infection is Encouraging Despite Endpoint Miss
-
Pfizer (PFE) Reiterated at Outperform by BMO Capital Following Earnings Report
-
Pfizer (PFE) PT Raised to $76 at BMO Capital, Reiterated as Top Pick, COVID 2022 Revenue Estimates Hiked to $63B from $40B
-
Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – Analyst
-
Pfizer (PFE) to Buy Arena Pharmaceuticals (ARNA) in a $6.7 Billion Deal, Pays a 100% Premium; Seen as the First of Many Acquisitions
-
COVID-19 Omicron Variant: Analysts Discuss Which Biopharma Stock is Best Positioned
-
UPDATE: BMO Capital Starts Pfizer (PFE) at Outperform
-
U.S. dollar weakens for fifth day on vaccine optimism
-
Sonoco Products (SON) PT Raised to $65 at BMO Capital Following News of Effective COVID Vaccine
-
Pre-Open Movers 07/20: (SRNE) (BNTX) (NBL) Higher; (NKLA) (MRNA) Lower (more...)
-
Pfizer (PFE) PT Lowered to $44 at BMO Capital
-
Pfizer (PFE) Risk/Reward Seems Favorable, But Not Enough for Upgrade - BMO
-
BMO Capital Reiterates Market Perform on Pfizer (PFE) Following Investor Meetings
-
BMO Capital Downgrades Pfizer (PFE) to Market Perform
-
Expert Call Increases Confidence In The Acceleration Of Pfizer's (PFE) ATTRCM Diagnosis Rate - BMO
-
Pfizer (PFE) PT Raised to $47 at BMO Capital; Sees Tafamidis as a $3.5B+ Drug
-
Olumiant 2mg FDA Approval is Incrementally Negative for AbbVie (ABBV) - BMO
-
Bari Adcom Negative for Eli Lilly (LLY) and AbbVie (ABBV), Positive for Pfizer (PFE) - BMO
-
Pfizer (PFE) PT Raised to $43 at BMO Capital
-
AbbVie (ABBV), Eli Lilly (LLY) More Vulnerable Than Other Drug Cos. on Amazon Entry - BMO
-
Pfizer (PFE) Not Hungry for a Large Deal - BMO
-
Pfizer (PFE) Should Buy Biogen (BIIB) Instead - BMO
-
Pfizer (PFE) PT Raised to $39 at BMO Capital
-
Pfizer (PFE) Consumer Health Unit Sale Would Be 'Incrementally Positive' - BMO
-
BMO Capital Upgrades Pfizer (PFE) to Outperform
-
If AstraZeneca (AZN) Soriot Rumors are True, It Becomes a Pfizer (PFE) Acquisition Target Again; Negative for Bristol-Myers (BMY)
-
Bristol-Myers Squibb (BMY) Takeover Less Likely Following Pfizer (PFE) Call - BMO
-
Pfizer (PFE): 4Q Should Be OK But Guidance Could Be Light - BMO
-
Complete Donald Trump Stock Impact Guide
-
Major Pharma Got a Major Win Last Night - BMO
-
BMO Capital Downgrades Pfizer (PFE) to Market Perform
-
BMO Capital Downgrades Pfizer (PFE) to Market Perform
-
Inflectra's U.S. Launch Incrementally Positive for Pfizer (PFE), Negative for AbbVie (ABBV) - BMO
-
Streetinsider.com's Hot Lunchtime Reads 9/30: (PEP) (OZM) (QCOM) (TSLA)
-
BMO 'Neutral to Positive' on Pfizer's (PFE) Medivation Takeover
-
Vertex (VRTX), BioMarin (BMRN), Intercept (ICPT), Others Highlighted as Targets at BMO Following PFE/MDVN
-
Pfizer beats estimates, but branded drugs disappoint
-
Notable Analyst Rating Changes 5/12: (AUY) (SNY) (WBMD) Upgraded; (ENSG) (M) (PMTS) Downgraded
-
Pfizer (PFE) Target Increases at BMO Capital Following a Good Quarter
-
BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination
-
After-Hours Stock Movers 04/05: (PLCM) (PFE) (AMGN) Higher; (CREE) (LINE) (WYNN) Lower (more...)
-
New Treasury Action Could Block, or Significantly Change Pfizer (PFE)/Allergan (AGN) Deal - BMO Capital
-
BMO Capital Reiterates Outperform on Pfizer (PFE) Following 4Q
-
EU Decision on Belgium Taxes Negative for the Group - BMO Capital (ZTS) (VRX) (LLY) (PFE)
-
Potential Allergan (AGN), Pfizer (PFE) Tie-Up No Surprise But May Take $400 to Get Done
-
BMO Capital Remains Bullish on Pfizer (PFE) as Split Becomes More Likely
-
Pfizer (PFE) PT Lifted to $41 at BMO Capital on Sum-of-the-Parts